These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29629912)

  • 21. 68Ga-PSMA Uptake by Dermatofibroma in a Patient With Prostate Cancer.
    Aydin F; Akçal A; Ünal B; Sezgin Göksu S; Güngör F
    Clin Nucl Med; 2017 May; 42(5):358-360. PubMed ID: 28240656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies: Has the Time Come to Remove "PS" From PSMA?
    Malik D; Kumar R; Mittal BR; Singh H; Bhattacharya A; Singh SK
    Clin Nucl Med; 2018 Jul; 43(7):529-532. PubMed ID: 29688950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of 5th minute and 2nd hour images to standard imaging in (
    Can C; Komek H
    Ann Nucl Med; 2020 Mar; 34(3):163-173. PubMed ID: 31808135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.
    Rauscher I; Maurer T; Fendler WP; Sommer WH; Schwaiger M; Eiber M
    Cancer Imaging; 2016 Jun; 16(1):14. PubMed ID: 27277843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
    Parida GK; Tripathy S; Datta Gupta S; Singhal A; Kumar R; Bal C; Shamim SA
    Clin Nucl Med; 2018 Apr; 43(4):248-249. PubMed ID: 29474196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.
    Herrmann K; Bluemel C; Weineisen M; Schottelius M; Wester HJ; Czernin J; Eberlein U; Beykan S; Lapa C; Riedmiller H; Krebs M; Kropf S; Schirbel A; Buck AK; Lassmann M
    J Nucl Med; 2015 Jun; 56(6):855-61. PubMed ID: 25883128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
    Park SY; Zacharias C; Harrison C; Fan RE; Kunder C; Hatami N; Giesel F; Ghanouni P; Daniel B; Loening AM; Sonn GA; Iagaru A
    Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
    Lin CY; Lee MT; Lin CL; Kao CH
    Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiphasic
    Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subacute Cortical Infarct Showing Uptake on 68Ga-PSMA PET/CT.
    Chan M; Hsiao E
    Clin Nucl Med; 2017 Feb; 42(2):110-111. PubMed ID: 27997426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
    Kulkarni SC; Sundaram PS; Padma S
    Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
    Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.
    Kanthan GL; Coyle L; Kneebone A; Schembri GP; Hsiao E
    Clin Nucl Med; 2016 Jun; 41(6):500-1. PubMed ID: 26914565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential Impact of
    Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
    J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidental Meningioma Mimicking Metastasis of Prostate Adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT.
    Bilgin R; Ergül N; Çermik TF
    Clin Nucl Med; 2016 Dec; 41(12):956-958. PubMed ID: 27824323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of PSMA Expression in Non-neuroendocrine Dedifferentiated Acinar Prostate Cancer.
    Bronsert P; Reichel K; Ruf J
    Clin Nucl Med; 2018 Jul; 43(7):526-528. PubMed ID: 29659395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-Specific Membrane Antigen-Negative Metastases-A Potential Pitfall in Prostate-Specific Membrane Antigen PET.
    Noto B; Auf der Springe K; Huss S; Allkemper T; Stegger L
    Clin Nucl Med; 2018 Jun; 43(6):e186-e188. PubMed ID: 29659383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
    Dewes S; Schiller K; Sauter K; Eiber M; Maurer T; Schwaiger M; Gschwend JE; Combs SE; Habl G
    Radiat Oncol; 2016 May; 11():73. PubMed ID: 27229485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.